Key Points - Capricor Therapeutics, Inc. (NASDAQ: CAPR) investors alerted to FDA review extension for Deramiocel amid an ongoing securities class action with a September 28 lead plaintiff deadline. - Multiple law firms remind investors of the upcoming deadline to file lead plaintiff applications in the class action lawsuit against Capricor Therapeutics. - The securities...
On KlickAnalytics's momentum model, Vaxart, Inc. (VXRT) scores 11/100, rated very weak, with 12-month performance doing...
Over the past month Anixa Biosciences, Inc. (ANIX) had 6 sessions that stood out against its...
Rather than pick a side, this is the evidence on each. Capricor Therapeutics, Inc. (CAPR) currently...
Most sessions tell you nothing. These 6 moved Allot Ltd. (ALLT) enough to be worth explaining...
from Lake Street issued a price target of $149.00 for SPRB on 2026-09-17 11:45:50.The adjusted price target was set to $149.00.At the time of the announcement, SPRB was trading at...
from Craig-Hallum issued a price target of $40.00 for PRE on 2026-09-17 11:13:33.The adjusted price target was set to $40.00.At the time of the announcement, PRE was trading at $22.02.The...
from Oppenheimer issued a price target of $7.00 for KOPN on 2026-09-17 10:40:40.The adjusted price target was set to $7.00.At the time of the announcement, KOPN was trading at $4.34.The...
Alexander Sklar from Raymond James issued a price target of $90.00 for RDVT on 2026-09-17 10:05:00.The adjusted price target was set to $90.00.At the time of the announcement, RDVT was...
from Roth Capital issued a price target of $17.00 for ABEO on 2026-09-17 08:31:39.The adjusted price target was set to $17.00.At the time of the announcement, ABEO was trading at...
In a landscape marked by rapid technological advancements, the company saw a revenue increase of $1.4 million for the three months ending September 30, 2024, fueled by new licenses and...
In a landscape of fluctuating revenues, the company celebrated a 25% revenue increase in Q3 2024, yet faced a 14% decline over nine months due to production challenges. Operating expenses...
In a landscape marked by financial challenges, the company faced fluctuating revenues, with a notable 25% increase in Q3 2024 overshadowed by a 14% decline over nine months. Operating losses...
In a tale of growth and ambition, the company witnessed its revenue soar from $6.0 million to $13.9 million, fueled by partnerships with Acadia Pharmaceuticals. However, operating expenses, particularly in...
In a transformative period, the company experienced a remarkable surge in revenue, driven by newly acquired oil and gas assets. Operating expenses showed notable trends, with a decrease in occupancy...
